No connection

Search Results

AMPH vs INMD

AMPH
Amphastar Pharmaceuticals, Inc.
BEARISH
Price
$18.18
Market Cap
$835.4M
Sector
Healthcare
AI Confidence
85%
INMD
InMode Ltd.
NEUTRAL
Price
$13.53
Market Cap
$857.2M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
AMPH
8.96
INMD
9.46
Forward P/E
AMPH
5.21
INMD
8.84
P/B Ratio
AMPH
1.05
INMD
1.25
P/S Ratio
AMPH
1.16
INMD
2.31
EV/EBITDA
AMPH
5.44
INMD
3.6

Profitability

Gross Margin
AMPH
49.46%
INMD
78.53%
Operating Margin
AMPH
19.45%
INMD
25.03%
Profit Margin
AMPH
13.63%
INMD
25.33%
ROE
AMPH
12.9%
INMD
13.53%
ROA
AMPH
6.37%
INMD
6.88%

Growth

Revenue Growth
AMPH
-1.8%
INMD
6.1%
Earnings Growth
AMPH
-31.0%
INMD
-63.5%

Financial Health

Debt/Equity
AMPH
0.83
INMD
0.01
Current Ratio
AMPH
4.02
INMD
9.88
Quick Ratio
AMPH
2.8
INMD
8.55

Dividends

Dividend Yield
AMPH
--
INMD
--
Payout Ratio
AMPH
0.0%
INMD
0.0%

AI Verdict

AMPH BEARISH

AMPH exhibits strong deterministic health with a Piotroski F-Score of 7/9, indicating solid operational efficiency and financial stability, though the absence of an Altman Z-Score raises concern about default risk. The stock trades at a discount to its Graham Number ($28.09) and intrinsic value ($14.21), suggesting undervaluation on a defensive basis. However, this is overshadowed by deteriorating fundamentals: negative revenue and earnings growth (YoY -1.8% and -31.0%), declining quarterly earnings, and a significant 36.4% drop in price over the past month. Insider selling activity further undermines confidence, with $0.95M in sales over six months despite no buy activity.

Strengths
Piotroski F-Score of 7/9 indicates strong financial health and operational efficiency
Graham Number of $28.09 suggests defensive undervaluation relative to intrinsic safety margin
High gross margin (49.46%) and operating margin (19.45%) reflect strong pricing power and cost control
Risks
Negative year-over-year earnings growth (-31.0%) and revenue decline (-1.8%) indicate deteriorating business momentum
Recent insider selling of $0.95M over six months signals potential lack of confidence from management
Stock has declined 36.4% in one month and 51.1% over three years, reflecting prolonged underperformance
INMD NEUTRAL

InMode presents a classic 'value trap' profile, characterized by a weak Piotroski F-Score of 3/9 and a completely bearish technical trend (0/100). While the company maintains an exceptional balance sheet with virtually no debt (Debt/Equity 0.01) and extreme liquidity (Current Ratio 9.88), these strengths are offset by a severe collapse in earnings growth (-63.50% YoY). The stock trades below its Graham Number ($18.63) but above its growth-based intrinsic value ($10.01), suggesting that while it is cheap on a book-value basis, its growth trajectory is deteriorating.

Strengths
Exceptional gross margins of 78.53%
Virtually debt-free balance sheet (Debt/Equity 0.01)
Extreme short-term liquidity with a Current Ratio of 9.88
Risks
Severe earnings contraction (-63.50% YoY)
Strongly bearish technical momentum (0/100 trend score)
Deteriorating fundamental health as indicated by Piotroski F-Score (3/9)

Compare Another Pair

AMPH vs INMD: Head-to-Head Comparison

This page compares Amphastar Pharmaceuticals, Inc. (AMPH) and InMode Ltd. (INMD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile